Avacta Group PLC's (LON:AVCT) Alastair Smith pitches the company to investors at the Proactive One2One Virtual Event.
Avacta has developed Affimer technology, an engineered alternative to antibodies.
Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets.